BioCryst Exceeds 2025 ORLADEYO Revenue Guidance, Projects Strong 2026 Growth

summarizeSummary

BioCryst Pharmaceuticals announced preliminary full-year 2025 ORLADEYO net revenue of $601 million, exceeding its prior guidance, and issued 2026 revenue and operating expense guidance, including the impact of the Astria Therapeutics acquisition.

check_boxKey Events

• Strong 2025 ORLADEYO Revenue Beat

  BioCryst reported preliminary, unaudited ORLADEYO net revenue of $601 million for full year 2025, surpassing its prior guidance range of $590 million to $600 million and representing 37% year-over-year growth.

• Positive 2026 Revenue Outlook

  The company provided full-year 2026 guidance, projecting global net ORLADEYO revenue between $625 million and $645 million, and total revenue (including RAPIVAB®) between $635 million and $660 million.

• 2026 Operating Expense Guidance

  Non-GAAP operating expenses for 2026 are estimated at $380 million to $390 million, increasing to $450 million to $470 million when including the expected impact of the Astria Therapeutics acquisition.

• Solid Cash Position

  As of December 31, 2025, preliminary cash, cash equivalents, restricted cash, and investments stood at $338 million.

auto_awesomeAnalysis

BioCryst Pharmaceuticals reported preliminary full-year 2025 ORLADEYO net revenue that surpassed its own guidance, indicating robust performance for its key product. The provided 2026 revenue guidance suggests continued growth, reinforcing the company's commercial trajectory. While operating expenses are expected to increase due to the Astria Therapeutics acquisition, the company's projection of continued non-GAAP profitability in 2026 signals confidence in its financial management and the strategic value of the acquisition. Investors should monitor the execution of the 2026 guidance and the integration of Astria Therapeutics.